ArticleEuroasian journal of hepato-gastroenterology
Hepatic Metastasis from Colorectal Cancer.
Article in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Pooled it
- Efficacy and Safety of Compound Kushen Injection for Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials with Trial Sequential Analysis.Integrative cancer therapiesPooled it
- Advances in liver transplantation for hepatic malignancies.Hepatic oncology · 2026Review
- Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells.Signal transduction and targeted therapy · 2026Article
- Tumoricidal efficacy of DZ-1 dye conjugated to dihydroartemisinin in patient-derived colorectal liver metastasis tumoroids.Molecular therapy. Oncology · 2026Article
- Tumor absorbed dose and outcomes after Y-90 glass radioembolization for colorectal liver metastases: does dose escalation improve survival in real-world practice?European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Multi-institutional study for comparison of detectability of hypovascular liver metastases between 70- and 40-keV images: DELMIO study.Abdominal radiology (New York) · 2026Article
- Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors.Cancer research communications · 2026Article
- Q.Liver software for the planning of treatment of liver cancer via transarterial radioembolization with yttrium-90 resin microspheres based on single-photon emission computed tomography-computed tomography.Quantitative imaging in medicine and surgery · 2026Article
- IER3 Promotes Malignant Progression of Colorectal Cancer Through the NF-International journal of genomics · 2026Article
- Prominent fibroblast growth factor 21 with less abundant tumor-associated macrophages in hepatic mass of the conditional mgmt-deleted mice using LysM-Cre system.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Integration of Untargeted Metabolomics, Network Pharmacology, Single-Cell RNA Sequencing, and Molecular Dynamics Simulation Reveals GOT1, CYP1A2, and CA2 as Potential Targets of Huang Qin Decoction Preventing Colorectal Cancer Liver Metastasis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- ATRA upregulates OTUD6B to recruit CD8Cell death & disease · 2025Article
- Prognostic Significance of mTOR Expression in Recurrence Following Hepatic Metastasectomy in Colorectal Cancer.Life (Basel, Switzerland) · 2025Article
- Lymphovascular invasion affects prognosis of colorectal cancer liver metastasis underwent primary resection: a propensity score matching analysis.BMC cancer · 2025Article
- A Network Based Model for Predicting Spatial Progression of Metastasis.Bulletin of mathematical biology · 2025Article
- Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come.Journal of surgical oncology · 2025Review
- Therapeutic Potentials of MiRNA for Colorectal Cancer Liver Metastasis Treatment: A Narrative Review.Iranian journal of medical sciences · 2025Review
- Lignans: Advances in Biosynthesis, Bioavailability, and Pharmacological Activity.Combinatorial chemistry & high throughput screening · 2025Review
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver is the most common site of metastasis in patients with colorectal cancer due to its anatomical situation regarding its portal circulation. About 14 to 18% of patients with colorectal cancer present metastasis at the first medical consultation, and 10 to 25% at the time of the resection of the primary colorectal cancer. The incidence is higher (35%) when a computed tomography (CT) scan is used. In the last decades, a significant increase in the life expectancy of patients with colorectal cancer has been achieved with different diagnostic and treatment programs. Despite these improvements, the presence of metastasis, disease recurrence, and advanced local tumors continue to remain poor prognostic factors. Median survival without treatment is <8 months from the moment of its presentation, and a survival rate at 5 years of 11% is the best prognosis for those who present with local metastasis. Even in patients with limited metastatic disease, 5-year survival is exceptional. Patients with hepatic metastasis of colorectal cancer have a median survival of 5 to 20 months with no treatment. Approximately 20 to 30% of patients with colorectal metastasis have disease confined to the liver, and this can be managed with surgery. Modern surgical strategies at the main hepatobiliary centers have proved that hepatectomy of 70% of the liver can be performed, with a mortality rate of <5%. It is very important to have knowledge of predisposing factors, diagnostic methods, and treatment of hepatic metastasis. However, the establishment of newer, efficient, preventive screening programs for early diagnosis and adequate treatment is vital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.